Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab in BCG-refractory NMIBC
NCT03759496Phase 2Unknown
- Sponsor
- Hellenic Genito-Urinary Cancer Group
- Start
- Nov 2018
- Primary completion
- May 2022
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of durvalumab in Non-muscle-invasive bladder cancer (NMIBC), sponsored by Hellenic Genito-Urinary Cancer Group. Status: unknown.
02
Drugs
durvalumab
03
Conditions
Non-muscle-invasive bladder cancer (NMIBC)
Beyond the preview
Go deeper on NCT03759496.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03759496.